Kresse SH, Meza-Zepeda LA, Machado I, Llombart-Bosch A, Myklebost O (2011) Cancer In press
Genomic validation of preclinical xenograft models of human sarcoma reveals recurrent loss of aberrations
Ballinger ML, Pattnaik S, Mundra PA, Zaheed M, Rath E, Priestley P, Baber J, Ray-Coquard I, Isambert N, Causeret S, van der Graaf WTA, Puri A, Duffaud F, Le Cesne A, Seddon B, Chandrasekar C, Schiffman JD, Brohl AS, James PA, Kurtz JE, Penel N, Myklebost O, Meza-Zepeda LA, Pickett H, Kansara Met al.(2023) Heritable defects in telomere and mitotic function selectively predispose to sarcomas Science, 379(6629), 253-260 DOI 10.1126/science.abj4784, PubMed 36656928
Venizelos A, Engebrethsen C, Deng W, Geisler J, Geisler S, Iversen GT, Aas T, Aase HS, Seyedzadeh M, Steinskog ES, Myklebost O, Nakken S, Vodak D, Hovig E, Meza-Zepeda LA, Lønning PE, Knappskog S, Eikesdal HP(2022) Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy Genome Med, 14(1), 86 DOI 10.1186/s13073-022-01090-2, PubMed 35948919
Misund K, Hofste Op Bruinink D, Coward E, Hoogenboezem RM, Rustad EH, Sanders MA, Rye M, Sponaas AM, van der Holt B, Zweegman S, Hovig E, Meza-Zepeda LA, Sundan A, Myklebost O, Sonneveld P, Waage A(2022) Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence Leukemia, 36(7), 1887-1897 DOI 10.1038/s41375-022-01597-y, PubMed 35643867